STOCK TITAN

Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Amicus Therapeutics to host conference call and webcast to discuss Q3 financial results
Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2023.

Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G


FAQ

When will Amicus Therapeutics host a conference call and webcast to discuss financial results for Q3 2023?

Amicus Therapeutics will host the conference call and webcast on Wednesday, November 8, 2023, at 8:30 a.m. ET.

How can participants access the call by phone?

Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, they will receive a dial-in number and personal PIN to access the event.

Where can the live audio webcast and presentation materials be accessed?

The live audio webcast and presentation materials can be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com.

When will the archived webcast and accompanying slides be available?

The archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

Amicus Therapeutics, Inc.

NASDAQ:FOLD

FOLD Rankings

FOLD Latest News

FOLD Stock Data

2.81B
222.12M
0.75%
109.94%
11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA

About FOLD

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g